Mechanistically, YAP acts in conjunction with TEAD to inhibit the expression of ZHX2 and its ability to bind p65, thereby blocking the cooperativity between ZHX2 and p65 required for NF-κB target gene expression and ccRCC growth. The gene discussed is ZHX2; the disease is nonpapillary renal cell carcinoma.